Thrombocytopenia Clinical Trials

24 recruiting

Thrombocytopenia Trials at a Glance

116 actively recruiting trials for thrombocytopenia are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 46 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Tianjin. Lead sponsors running thrombocytopenia studies include Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital, and University Hospital, Bordeaux.

Browse thrombocytopenia trials by phase

Treatments under study

About Thrombocytopenia Clinical Trials

Looking for clinical trials for Thrombocytopenia? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thrombocytopenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thrombocytopenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 116 trials

Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Immune Thrombocytopenia
Sanofi60 enrolled24 locationsNCT07007962
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
argenx69 enrolled94 locationsNCT06544499
Recruiting
Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China224 enrolled1 locationNCT04518475
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Patients With Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.150 enrolled7 locationsNCT07286032
Recruiting
Phase 3

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Shandong University86 enrolled1 locationNCT07559331
Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPITP - Immune Thrombocytopenia+1 more
argenx24 enrolled8 locationsNCT07194850
Recruiting
Phase 1Phase 2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting

Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion

TraumaThromboembolusMassive Blood Transfusion; Thrombocytopenia
Zeliha Alicikus4 enrolled2 locationsNCT07290634
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Early Phase 1

Apixaban in Thrombocytopenia

ThrombocytopeniaDeep Vein ThrombosisPulmonary Embolism and Thrombosis+1 more
Rushad Patell30 enrolled1 locationNCT06886516
Recruiting
Phase 3

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC39 enrolled21 locationsNCT06449651
Recruiting
Phase 3

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

CTIT: Cancer Therapy Induced Thrombocytopenia
The First Affiliated Hospital with Nanjing Medical University88 enrolled1 locationNCT06759636
Recruiting
Phase 3

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC50 enrolled24 locationsNCT06533098
Recruiting
Phase 3

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.36 enrolled9 locationsNCT07233213
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Not Applicable

Neonatal Platelet Transfusion Threshold Trial

ThrombocytopeniaNeonatal
NICHD Neonatal Research Network2,433 enrolled20 locationsNCT06676904
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 2

Luspatercept for Clonal Cytopenias of Uncertain Significance

ThrombocytopeniaNeutropeniaAnemia+2 more
Weill Medical College of Cornell University50 enrolled1 locationNCT06788691
Recruiting
Phase 2

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Changhai Hospital40 enrolled1 locationNCT07492693
Recruiting
Early Phase 1

Single Arm Romiplostim to Prevent CIT

Ewings SarcomaChemotherapy Induced Thrombocytopenia
Children's Hospital Medical Center, Cincinnati26 enrolled2 locationsNCT07048249